In breast cancer cells, 17-b-estradiol (E2) upregulates the expression of insulin receptor substrate 1 (IRS-1), a molecule transmitting insulin-like growth factor-I (IGF-I) signals through the PI-3K/Akt survival pathways. The stimulation of IRS-1 by E2 has been documented on the transcriptional level. Here we studied whether the expression of estrogen receptor (ER)-a affects IRS molecules post-transcriptionally. We used ER-a-negative MDA-MB-231 breast cancer cells and MDA-MB-231 cells with re-expressed ER-a. In MDA-MB-231 cells cultured under serum-free conditions, IRS-1 and IRS-2 were degraded through the 26S proteasome and calpain pathways. Re-expression of ER-a in MDA-MB-231 cells correlated with enhanced stability of IRS molecules. This effect coincided with significantly reduced ubiquitination of IRS-1 and IRS-2, but did not involve increased IRS-1 and IRS-2 transcription. The interference of ER-a with IRS-1 and IRS-2 turnover could rely on the competition for common degradation pathways, as in MDA-MB-231/ ER cells, ER-a processing was blocked by proteasome and calpain inhibitors. Notably, a fraction of the cytosolic ERa colocalized and coprecipitated with IRS-1 and IRS-2, indicating a possible common destination for these proteins. The stabilization of IRS-1 in MDA-MB-231/ ER cells was paralleled by the upregulation of the IRS-1/ Akt/GSK-3 pathway and improved survival in the presence of IGF-I, whereas IRS-2 was not involved in IGF-I signaling.
Introduction
Insulin receptor substrates (IRS) 1 and 2, members of the IRS family of signaling molecules, are major signaling intermediates of the insulin and insulinlike growth factor I (IGF-I) receptors (IR and IGF-IR) . In addition, IRS-1 and IRS-2 transmit signals of many other receptors (e.g., prolactin, growth hormone, several interleukins, and interferons, a6b4 integrins) (Yenush and White, 1997; Aguirre and White, 2000; Burks and White, 2001; Shaw, 2001) . In response to ligand binding, IRS substrates are tyrosine phosphorylated, which results in sequestration of multiple effector molecules and stimulation of different signaling pathways (Yenush and White, 1997; Aguirre and White, 2000; Burks and White, 2001) . The most notable is the PI-3K/Akt pathway that regulates cell growth and survival as well as different nonmitogenic functions in various cell systems (Shepherd et al., 1998) Although the functions of IRS-1 and IRS-2 can partially overlap, the data obtained with knockout animals indicated that IRS-1 and IRS-2 may have unique roles (Burks and White, 2001; Fasshauer et al., 2001) .
Aberrant expression of IRS molecules has been associated with pathogenesis of diabetes as well as with the development of cancer of the breast, pancreas, and liver (Sasaki et al., 1993; Bergmann et al., 1996; Kornmann et al., 1998; Spector et al., 1999; Aguirre and White, 2000; Surmacz, 2000; Ducluzeau et al., 2001; Sachdev and Yee, 2001 ). However, the mechanisms controlling cellular abundance of these substrates are only partially known. Recent studies indicated that the expression of IRS-1 and IRS-2 is developmentally regulated and cell context-dependent, and may involve transcriptional and post-transcriptional events (Giovannone et al., 2000) . For instance, 17-b-estradiol (E2) has been shown to increase IRS-1 mRNA expression, while antiestrogens decrease IRS-1 mRNA levels (Guvakova and Surmacz, 1997; Lee et al., 1999; Salerno et al., 1999; Molloy et al., 2000; Surmacz, 2000; Mauro et al., 2001; Sachdev and Yee, 2001) . Glucocorticoids inhibit IRS-1, but stimulate IRS-2 mRNA expression (Turnbow et al., 1994; Dupont et al., 1999; Sakoda et al., 2000) . Furthermore, IRS-2 transcription can be induced by progesterone and PPAR gamma agonists and inhibited by insulin (Vassen et al., 1999; Smith et al., 2001; Zhang et al., 2001) .
In addition to the transcriptional control, cellular abundance of IRS proteins is regulated by posttranscriptional mechanisms, especially those controlling protein processing. For instance, in 3T3-L1 adipocytes, chronic exposure to insulin increased IRS-1 serine/ threonine phosphorylation and resulted in IRS-1 degradation through the 26S proteasome (Sun et al., 1999; Pederson et al., 2001) . Similarly, prolonged exposure of MCF-7 breast cancer cells and prostate epithelial cells to IGF-I increased IRS-1 ubiquitination and subsequent degradation in a 26S proteasomedependent manner (Lee et al., 2000; Zhang et al., 2000) . Other study with 3T3-L1 cells implicated calpain, a calcium-dependent neutral protease, in the degradation of IRS-1 in response to chronic insulin treatment (Smith et al., 1993 (Smith et al., , 1996 . The lysosomal pathway has been reported as not involved in IRS-1 processing (Rice et al., 1993) .
IRS-2 has been described to undergo degradation through the 26S proteasome in 3T3-L1 cells, Fao hepatoma cells, mouse embryo fibroblasts (Rui et al., 2001) and mouse uterine cells (Richards et al., 2001) . However, in CHO cells, prolonged insulin exposure did not affect IRS-2 stability, while it resulted in proteasomal processing of IRS-1 (Sun et al., 1999) .
The proliferation and survival of hormone-responsive breast cancer cells is influenced by crosstalk between the estrogen receptor-a (ER-a) and IGF-IR. An important feature of this interplay is upregulation of IGF-IR signaling by activated ER-a (Surmacz, 2000; Sachdev and Yee, 2001) . Especially, E2 has been shown to increase transcription and expression of IRS-1, potentiating the IRS-1/PI-3K/Akt pathway (Lee et al., 1999; Surmacz, 2000; Sachdev and Yee, 2001 ). The regulation of IRS molecules by ER-a on the post-transcriptional level, especially on the level of protein degradation, has not been studied and is a subject of this work. Considering that the 26S proteasome and calpain pathways have been implicated in the degradation of ER-a (Murayama et al., 1984; Shiba et al., 1996; Nawaz et al., 1999; Lonard et al., 2000) , we explored the idea that ER-a and IRS substrates may compete for the same degradation processes. To better distinguish between the transcriptional and post-transcriptional regulation of IRS-1 and IRS-2 by ER-a, we developed MDA-MB-231/ER breast cancer cells, in which ER-a does not affect IRS-1 and IRS-2 mRNA synthesis. The degradation of IRS-1 and IRS-2 was studied in MDA-MB-231/ER cells and compared to that in ER-a-negative MDA-MB-231 cells.
Results
Re-expression of ER-a in MDA-MB-231 cells coincides with decreased degradation of IRS-1 and IRS-2 MDA-MB-231 cells are ER-a-negative breast cancer cells expressing IRS-1 and IRS-2. To investigate the expression of IRS substrates in the presence or absence of ER-a, we reintroduced ER-a into MDA-MB-231 cells by stable transfection. Several clones positive for ER-a expression were pooled to generate a mixed population of MDA-MB-231/ER cells. In growing MDA-MB-231/ ER cells (day 0), the levels of IRS-1 and IRS-2 were greater than that in the parental ER-a-negative cells ( Figure 1a ) During cell culture in SFM, the abundance of IRS-1 and IRS-2 in MDA-MB-231 cells further declined, reaching minimal levels at day 3, when the To investigate whether the increased abundance of IRS-1 and IRS-2 in the presence of ER-a reflected increased transcription, the expression of IRS-1 and IRS-2 mRNAs was assessed by RT-PCR at days 0, 1, and 3. At all time points, the abundance of the PCR products obtained at 25 and 35 cycles was similar in MDA-MB-231 and MDA-MB-231/ER cells, indicating that re-expression of ER-a did not affect IRS-1 and IRS-2 on the transcriptional level (Figure 1b) .
Consequently, we explored the possibility that the presence of ER-a might affect the stability of IRS-1 and IRS-2. We measured the half-life of the IRS molecules by 35 S pulse-chase labeling. Under SFM conditions, the half-life of IRS-1 in MDA-MB-231 cells was B3 h, while in MDA-MB-231/ER cells B10 h (Figure 1c ) ERa increased the half-life of IRS-2 by B6 h in our cell models (data not shown).
Degradation of IRS-1, IRS-2, and ER occurs through the 26S proteasome and calpain pathways
To study the degradation pathways of IRS-1 and IRS-2 in MDA-MB-231/ER cells, we used specific blockers of the proteasome and calpain pathways. Treatment of the cells with either 10 mm MG 132, a 26S proteasome inhibitor, or 20 nm calpastatin, a calpain inhibitor, resulted in the accumulation of IRS-1 and IRS-2, indicating that these two pathways are involved in the processing of the IRS substrates. In the case of IRS-1, both MG 132 and calpastatin increased IRS-1 levels by approximately 2.8-and 3.0-fold, respectively (Figure 2a ). IRS-2 levels were enhanced by B5.0-fold in the presence of MG 132 and by B4.0-fold in calpastatin-treated cells. The addition of 10 nm E2 did not affect the expression of IRS-1 in a significant way, while it reduced slightly the amounts of IRS-2 in MG 132 and calpastatin-treated cells (Figure 2a ).
The inhibitors of the 26S proteasome and calpain were also employed to assess ER-a degradation. In the presence of MG 132, ER-a levels were significantly (B5.0-fold) increased, while calpastatin treatment resulted in 2.5-fold upregulation of ER-a expression ( Figure 2b ). Concurrent with published observations (Nawaz et al., 1999) , stimulation with E2 significantly reduced (by B50%) ER-a levels. Interestingly, this effect of E2 on ER-a was also evident in MG 132 and calpastatin-treated cells (Figure 2b ). The observation that the inhibition of individual proteolytic processes was not sufficient to abolish E2 action suggested that multiple pathways are involved in E2-dependent degradation of ER-a. None of the treatments affected the expression of b-actin in MDA-MB-231/ER cells (Figure 2a and b).
Ubiquitination of IRS-1 and IRS-2 is significantly reduced in the presence of ER-a
Ubiquitination of proteins marks them for the recognition by the 26S proteasome (Joazeiro and Hunter, 2000) . Treatment with MG 132, which blocks the 26S proteasome activity, results in the accumulation of ubiquitinated proteins. We analysed the ubiquitination of IRS-1, IRS-2, and ER-a in the presence or absence of MG 132 in MDA-MB-231 and MDA-MB-231/ER cells ( Figure 3a , b, and c). In ER-a-negative MDA-MB-231 cells, IRS-1 and IRS-2 were ubiquitinated in MG 132-treated cells, and the addition of E2 did not affect this process. In contrast, in MDA-MB-231/ER cells, the ubiquitination of the IRS proteins in the presence of MG 132 was dramatically decreased with or without E2 (Figure 3a and b). The results suggested that in the presence of ER-a, the proteasome-dependent degradation of IRS-1 and IRS-2 might be inhibited at the step of ubiquitination. This could occur if the elements of the ubiquitination cascade involved in IRS-1 and IRS-2 processing were sequestered by reexpressed ER-a. Subsequent experiments indicated that ER-a was ubiquitinated in MG 132-treated MDA-MB-231/ER cells (Figure 3c ). In the presence of E2, the ubiquitination was reduced, most likely reflecting ligand-induced downregulation of ER-a expression (Figures 3c and 2b) .
The effect of ER-a expression on the ubiquitination of IRS-1 and IRS-2 was at least partially specific, as it did Following the treatment, the cells were lysed and 25 mg of total protein lysates were analysed by WB with specific Abs to detect IRS-1 and IRS-2 (a), and ER-a (b). To control for protein loading, the blots in (a) and (b) were stripped and re-probed with anti-bactin Ab. The graphs represent the expression of each protein (7s.e.) relative to the expression of actin measured by laser scanning. The experiments were repeated four times ER-a regulates degradation of IRS-1 and IRS-2 C Morelli et al not reduce total protein ubiquitination, or the ubiquitination of other proteins that are normally degraded through proteasome-dependent pathways (Figure 3d , e, and f). For instance, the ubiquitination of b-catenin and heat shock protein 90 (Hsp 90), both targets of the 26S proteasome (Aberle et al., 1997; Ashok et al., 2001) , were comparable in MDA-MB-231 and MDA-MB-231/ ER cells ER (Figure 3e and f) . Similarly, ER-a did not affect ubiquitination of Hsp 70 and IRS-4 (data not shown).
IRS-1 and IRS-2 colocalize and coprecipitate with ER-a
Since ER-a appeared to affect the processing of IRS-1 and IRS-2, we studied whether all these proteins reside within the same cellular compartment. Using confocal microscopy and subcellular fractionation, we found that in untreated MDA-MB-231/ER cells, ER-a is present in the cytoplasm as well as in the nucleus, while IRS-1 and IRS-2 were mostly cytoplasmatic (Figure 4a and b, and unpublished data). Small amounts of IRS-1 and IRS-2 Figure 3 ER-a expression coincides with reduced ubiquitination of IRS-1 and IRS-2 in MDA-MB-231/ER cells. MDA-MB-231 and MDA-MB-231/ER cells were treated for 1 day with either E2 (10 nm), MG 132 (10 mm), E2 plus MG 132, or DMSO (7 mm) (control treatment) and then lysed. IRS-1 (a), IRS-2 (b), or ER-a (c) were immunoprecipitated from 1 mg of protein lysates, and their levels and ubiquitination were evaluated by WB with specific Abs, as described in Materials and methods. The ubiquitination of total cytoplasmic proteins (d) was studied by WB in 50 mg of protein lysates obtained from MDA-MB-231 and MDA-MB-231/ER cells treated with MG 132 (10 mm) or DMSO (7 mm). The same lysates (500 mg) were used to immunoprecipitate b-catenin (beta-cat) (e) and Hsp 90 (f) and analyse their ubiquitination by WB with appropriate Abs. The data are representative of at least three experiments.
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C Morelli et al were present in the nucleus of MDA-MB-231/ER cells, while nuclear IRS-1 and IRS-2 were undetectable in MDA-MB-231 cells (Figure 4b ), confirming recent reports that IRS molecules can translocate to the nuclear compartment when coexpressed with nuclear proteins (Lassak et al., 2002; Prisco et al., 2002) . In MDA-MB-231/ER cells, a significant fraction (B30%) of IRS-1 colocalized with ER-a in the cytoplasm (Figure 4a ). Similar colocalization was found for IRS-2 and ER-a (data not shown).
The subsequent experiments demonstrated that in MDA-MB-231/ER cells, ER-a can be found in IRS-1 and IRS-2 immunoprecipitates, while it cannot be detected in IRS-1 or IRS-2 precipitates from ER-a-negative MDA-MB-231 cells (Figure 4c) . In a complementary experiment, we located IRS-1 and IRS-2 in ER-a precipitates in MDA-MB-231/ER cells (Figure 4d ). Consistent with our previous findings (Figures 2 and 3) , the abundance of ER-a : IRS-1 and ER-a : IRS-2 complexes was always significantly greater in MG 132-treated cells, and reflected increased accumulation of IRS-1, IRS-2, and ER-a in the presence of the proteasome 26S inhibitor (Figure 4c and d) . To confirm that a fraction of ER-a can associate with IRS-1 and IRS-2, depletion experiments were performed, where the expression of ER-a was probed in cytosolic lysates before and after IRS-1 or IRS-2 precipitation. We found that depletion of IRS-1 and IRS-2 significantly (B35 and B25%, respectively) reduced cytoplasmic abundance of ER-a (Figure 4e ).
Re-expression of ER-a coincides with better cell survival in the presence of IGF-I Previous results suggested that re-expression of ER-a decreases IRS-1 and IRS-2 turnover. Here, we addressed the biologic consequences of this phenomenon. Growth profiles confirmed our previous observations that MDA-MB-231 cells die in SFM in the presence or absence of IGF-I (Bartucci et al., 2001) ; however, compared with the parental cells, MDA-MB-231/ER cells exhibited significantly better survival in the presence of IGF-I (Figure 5a ). This effect coincided with increased IGF-I-dependent tyrosine phosphorylation of IRS-1, increased activity of Akt, and enhanced serine phosphorylation of GSK3 a/b (at 15 min and 1 day of treatment). The upregulation of the Akt/GSK-3 pathway in the presence of ER-a was noted in several experiments and was statistically significant. The increased activation of Akt was paralleled by downregulation of ERK1/2 at 1 day (Figure 5b ), which was in agreement with previously published observations obtained with this and other cellular models (Rommel et al., 1999; Zimmermann and Moelling, 1999; Bartucci et al., 2001) . Interestingly, in MDA-MB-231/ER cells, IRS-2 tyrosine phosphorylation was not stimulated upon IGF-I treatment (data not shown), confirming findings obtained in other breast cancer cell models (Jackson et al., 1998) . The expression of IRS-1, IRS-2, and ER-a was studied in 50 mg of cytoplasmic (C) and nuclear (N) protein lysates obtained from MDA-MB-231 (231) and MDA-MB-231/ER (231/ER) cells. The expression of a nuclear protein, c-Jun, and a cytoplasmic enzyme, GAP-DH, was assessed (upon stripping and reprobing of the filters) to control the purity of fractions. The graph represents relative abundance of each protein (7SE). (c) MDA-MB-231 and MDA-MB-231/ER cells were treated for 1 day with 10 mm MG 132 or 7 mm DMSO and then lysed. IRS-1 and IRS-2 were immunoprecipitated from 1 mg of protein lysates and their association with ER-a was probed by WB with anti-ER-a mAb. In parallel, the expression of ER-a in the cell lines was studied by WB in 50 mg of whole protein lysates. (d) ER-a was immunoprecipitated from 1 mg of protein lysates and its association with IRS-1 and IRS-2 was evaluated by WB with anti-IRS-1 and -IRS-2 Abs. The expression of IRS-1 and IRS-2 in the cells was detected by WB in 25 mg of whole cell lysates. In (c) and (d) the control samples were precipitated with carrier beads only (protein A agarose and anti-mouse IgG agarose for IRS molecules and ER-a, respectively), with the omission of the primary Abs, and then processed for WB. (e) The expression of ER-a was studied in 50 mg of cytoplasmic lysates before and after IP of IRS-1, IRS-2, or ER-a. The expression of the cytoplasmic protein GAP-DH is shown as a control of loading. The graph represents the expression of each protein relative to the expression of GAP-DH ER-a regulates degradation of IRS-1 and IRS-2 C Morelli et al Discussion IRS-1 and IRS-2 are expressed in the majority of breast cancer cell lines and have been identified in most breast tumor samples (Jackson et al., 1998; Lee et al., 1999; Molloy et al., 2000; Surmacz, 2000; Jackson et al., 2001; Sachdev and Yee, 2001) . In ER-a-positive breast cancer cells, IRS-1, through the activation of downstream kinases PI-3 and ERK1/2, mediates mitogenic signaling of IGF-I (Surmacz, 2000; Sachdev and Yee, 2001) , whereas the function of IRS-2 is unclear. Recent data suggested that IRS-2 might be necessary to transmit nonmitogenic signals of IGF-I, such as stimulation of cell migration (Jackson et al., 2001) .
The expression and activation of ER-a has been shown to enhance insulin and IGF-I mitogenicity (Lee et al., 1999; Surmacz, 2000; Mauro et al., 2001; Sachdev and Yee, 2001) . It is now well established that one important mechanism by which ER-a amplifies the effects of IGF-I and insulin is upregulation of the expression and function of IRS-1 (Lee et al., 1999; Molloy et al., 2000; Surmacz, 2000; Mauro et al., 2001; Sachdev and Yee, 2001 ). For instance, in MCF-7 breast cancer cells, the activation of ER-a by E2 stimulated the expression of IRS-1 and potentiated IRS-1 signaling through the PI-3K/Akt pathway. These effects were blocked in the presence of antiestrogens (Lee et al., 1999; Salerno et al., 1999; Molloy et al., 2000; Mauro et al., 2001) . The upregulation of IRS-1 by E2 has been documented on the transcriptional level (Lee et al., 1999; Molloy et al., 2000; Mauro et al., 2001 ). E2 did not influence the expression of IRS-3 and IRS-4 mRNAs and proteins, and the stimulation of IRS-2 expression, although noted, has been found statistically insignificant (Molloy et al., 2000) .
The regulation of IRS-1 and IRS-2 by ER-a on the post-transcriptional level has never been studied and has been addressed in this work. To distinguish between transcriptional and post-transcriptional effects, we reexpressed ER-a in ER-a-negative MDA-MB-231 cells to develop MDA-MB-231/ER cells. In this cellular model, the presence of ER-a (unliganded) did not affect the expression of IRS-1 and IRS-2 mRNAs.
The experiments with MDA-MB-231/ER cells yielded novel information on the interaction between ER-a and IRS substrates. Especially, we found that (1) ER-a reexpression coincided with higher basal levels of IRS-1 and IRS-2; (2) under SFM conditions, the amounts of IRS-1 and IRS-2 declined only in the absence of ER-a; (3) re-expression of ER-a increased IRS-1 and IRS-2 half-life but did not affect IRS-1 and IRS-2 mRNA levels; (4) in MDA-MB-231/ER cells, degradation of IRS-1, IRS-2, and ER-a proceeded through common proteolytic pathways and a fraction of IRS-1 and IRS-2 was found to associate with ER-a; (5) ER-a reexpression was paralleled by reduced ubiquitination of IRS-1 and IRS-2; (6) higher levels of IRS-1 in MDA-MB-231/ER cells improved long-term activation of the IRS-1/Akt pathway and cell survival in IGF-I.
In MDA-MB-231/ER cells, the addition of E2 significantly reduced ER-a levels indicating that reexpressed ER-a could be liganded and then targeted for degradation, as normally observed in ER-a expressing cells (Nawaz et al., 1999; Lonard et al., 2000) . The Figure 4 Continued.
C Morelli et al degradation of the liganded ER-a has been described to occur through the 26S proteasome, whereas under basal conditions in vitro, the degradation of ER-a may involve calpain pathways (Murayama et al., 1984; Shiba et al., 1996; Nawaz et al., 1999; Lonard et al., 2000) . Our observations that E2 stimulated degradation of ER-a were consistent with other reports. However, we noticed that the degradation of ER-a both ligand-dependent and -independent was reduced in the presence of 26S proteasome and calpain inhibitors, implicating both pathways hi these processes. The differences could reflect the experimental models, as proteasomal degradation of ER-a has been documented in transfected HeLa cells, and calpain proteolysis has been described in the case ER-a purified from porcine uterus (Murayama et al., 1984; Nawaz et al., 1999; Lonard et al., 2000) . Since re-expression of ER-a coincided with greater abundance and stability of IRS-1 and IRS-2 proteins, but not with increased transcription of the corresponding mRNAs, we investigated whether ER-a inhibits IRS-1 and IRS-2 degradation. In our experimental model, IRS-1 and IRS-2 were processed through the 26S proteasome and calpain pathways, which corroborated results obtained with other models (Smith et al., 1996; Sun et al., 1999; Lee et al., 2000; Zhang et al., 2000; Pederson et al., 2001) . Since ER-a is processed through the same mechanisms, we hypothesized that re-expressed ER-a could downregulate the degradation of IRS-1 and IRS-2 by sequestration of enzymes or other proteins involved in common proteolytic processes. Our finding that the presence of ER-a inhibits the ubiquitination of IRS-1 and IRS-2 seems to support this possibility. Interestingly, the effects of ER-a were at least partially specific, as reexpression of ER-a did not affect total protein ubiquitination, or the ubiquitination of several other proteins normally degraded through an MG 132-sensitive pathway, for example, b-catenin (Aberle et al., 1997) , Hsp 90, and Hsp 70 (Ashok et al., 2001 ). Figure 5 Re-expression of ER-a in MDA-MB-231 cells coincides with better survival in the presence of IGF-I. MDA-MB-231 and MDA-MB-231/ER were synchronized in PRF-SFM and treated with IGF-I as described in Materials and methods. The graphs demonstrate cell numbers at 0, 1, 2, and 3 days of treatment. Growth assays were repeated three times, SE values are shown as error bars (a). Tyrosine phosphorylation of IRS-1 was measured by IP and WB at 0, 15 min, and 1 day of IGF-stimulation. The phosphorylation of Akt, GSK3, and ERK1/2 and total levels of Akt, ERK1/2, b-actin were assessed at the same time points by WB in 50 mg of whole-cell lysates using Abs described in Materials and methods (b)
ER-a regulates degradation of IRS-1 and IRS-2 C Morelli et al
The stabilization of IRS molecules in the presence of ER-a appears to be biologically significant, especially for the IGF-I phenotype. Our data suggest that MDA-MB-231/ER cells, when compared with MDA-MB-231 cells, are characterized by improved cell survival in IGF-I, enhanced tyrosine phosphorylation of IRS-1, and improved activation of the downstream Akt/GSK-3 pathway. We speculate that the restoration of this pathway was incomplete because some IGF-I effects that are characteristic for normal ER-a-positive cells (e.g., vigorous growth in IGF-I or IGF-IR/PI-3K-dependent degradation of IRS-1) were not observed. The lack of IRS-2 activation by IGF-I confirmed findings in other breast cancer cells (Jackson et al., 1998) .
Since the IRS-1, IRS-2, and ER-a are degraded by common mechanisms, we analysed, using several different techniques, whether these proteins can be found in one cellular compartment. By confocal microscopy and subcellular protein fractionation, we determined that in unstimulated MDA-MB-231/ER cells, IRS-1, IRS-2, as well as a fraction of ER-a are found in the cytoplasm. The cytoplasmic presence of these molecules has been additionally confirmed by immunocytochemistry (data not shown). Our confocal microscopy and immunoprecipitation experiments suggested a physical interaction between ER-a and the IRS proteins. The association of ER-a with cytoplasmic signaling molecules is not unusual; for instance, ER-a has been shown to interact with the IGF-IR (Kahlert et al., 2000) , PI-3 K (Simoncini et al., 2000; Sun et al., 2001) , and SHC (Song et al., 2002) , in all cases, enhancing the signaling potential of these molecules in cell stimulated with growth factors (Simoncini et al., 2000; Sun et al., 2001) . Our experiments as well as data from other laboratories (Simoncini et al., 2000; Sun et al., 2001) suggest that only a fraction of ER-a interacts with cytoplasmic signaling proteins. The immunoprecipitation and microscopic techniques suggested that approximately 20-30% of ER-a can associate with IRS molecules. Our recent experiments indicate that the ER-a : IRS-1 and ER-a : IRS-2 complexes are not unique to MDA-MB-231/ER cells as they also exist in MCF-7 cells and other ER-a-positive breast cancer cell lines and are regulated by E2 (Morelli et al., unpublished data) .
In summary, the expression of ER-a could decrease proteolytic turnover of IRS molecules. We hypothesize that ER-a : IRS-1/2 complex formation represents one of the stages of the common degradation processes. The post-transcriptional interactions between ER-a and IRS-1 exemplify a new aspect of ER/IGF-IR crosstalk and a possible target in breast cancer therapy.
Materials and methods

Plasmids
The pcDNA3-ER expression plasmid (obtained from Dr Diego Sisci, University of Calabria, Italy) encodes the wildtype ER-a under the CMV promoter and contains a neomycin resistance gene.
Cell lines
MDA-MB-231 cells were obtained from ATCC. MDA-MB-231/ER clones were developed by stable transfection of MDA-MB-231 cells with the plasmid pcDNA3-ER using Fugene 6 transfection reagent (Roche) (DNA : Fugene 6 ratio was 1 mg : 3 ml). Transfectants resistant to 2 mg/ml G418 (Gibco) were screened for ER-a expression by Western blotting (WB) using an anti-ER-a mouse monoclonal antibody (mAb) F-10 0.2 mg/ml (Santa Cruz). To avoid clonal variation, we used a mixed population of five ER-a-expressing clones (referred to as MDA-MB-231/ER cells).
Cell culture
MDA-MB-231 cells were grown in DMEM : F12 containing 5% calf serum (CS). MDA-MB-231/ER cells were cultured in DMEM : F12 plus 5% CS plus 500 mg/ml G418. In the experiments requiring E2-and serum-free conditions, the cells were cultured in phenol red-free serum-free medium (SFM) (Guvakova and Surmacz, 1997; Salerno et al., 1999) .
Growth curves
The cells were plated in six-well plates at a concentration of 1.5-2.0 Â 10 5 cells/plate in normal growth medium. The following day (day 0), the cells at approximately 50% confluence were shifted to SFM containing 50 ng/ml IGF-I. Cell number was determined at days 0, 1, 2, and 3. A fresh dose of IGF-I was added each day.
RT-PCR
Total cellular RNA was extracted from cells cultured for 0, 1, and 3 days using RNeasy Mini Kit (Qiagen). RNA (1 mg) was reverse transcribed (RT) and then amplified by PCR to obtain products corresponding to cDNA fragments of IRS-1, IRS-2, or b-actin. RT-PCR was performed using the Superscript First Strand synthesis system (Gibco) and PCR Core kit (Roche). The following primers were used: IRS-1 upstream primer 5 0 -TCCACTGTGACACCAGAATAAT-3 0 (nt 4979-5000, human IRS-1 cDNA; Araki et al., 1993) 0 -TTTCACGGTTGGCCTTAGGGTT-3 0 (nt 411-433). PCR was performed in a GeneAmp PCR System 9600 thermocycler (Perkin-Elmer) using the following conditions: for IRS-1, 1 min at 941C, 1 min at 501C, 2 min at 721C; for IRS-2, 30 s at 941C, 30 s at 481C, 40 s at 721C; for b-actin, 1 min at 941C, 1 min at 501C, 2 min at 721C. The amplification products obtained in 15, 25, and 35 cycles were analysed in a 1% agarose gel.
Treatment with inhibitors of protein degradation
Confluent cultures (70%) were shifted to SFM and treated for 24 h with MG132 and calpastatin in the presence or absence of E2. MG132 (carbobenzoxy-l-leucyl-l-leucyl-l-leucinal) (Calbiochem) is an inhibitor of the 26S proteasome and was used at the concentration of 10 mm. Calpastatin (a 27 residue peptide encoded by exon 1B of human calpastatin) (Calbiochem) is an inhibitor of calpains I and II, and was used at the concentration 20 nm. E2 (Sigma) was used at the concentration 10 nm. Control cultures were treated with 7 mm DMSO (ICN Biomedicals).
Immunoprecipitation and WB
Cell cultures (70%) were shifted to SFM for 0-72 h and then lysed. Cytoplasmic protein lysates were obtained with a buffer containing 50 mm HEPES, pH 7.5, 150 mm NaCl, 1% Triton X-100, 1.5 mm MgCl 2 , EGTA 10 mm pH 7.5, glycerol 10%, inhibitors (2 mm Na 3 VO 4 , 1% PMSF, 20 mg/ml aprotinin). Following the collection of cytoplasmic proteins, the nuclei were lysed with the buffer containing 20 mm KOH-HEPES pH 8, 0.1 mm EDTA, 5 mm MgCl 2 , 0.5 m NaCl, 20% glycerol, 1% NP-40, and inhibitors (as above). The expression of target proteins was analysed by WB using 25-50 mg of cell lysate and/ or by IP in 500 mg-1 mg of lysate. The following antibodies (Abs) were used: anti-IRS-1 polyclonal Ab (pAb) (UBI) for WB and IP; anti-IRS-2 pAb (UBI) for WB and IP; anti-ER-a mAb (Santa Cruz) for WB and IP; anti-b-catenin mAb (Transduction Laboratories) for WB and IP; anti-b-actin mAb (Sigma) for WB, anti-ubiquitin mAb (Santa Cruz) for WB; anti-Hsp 90 mAb (Santa Cruz) for WB and IP; anti-active Akt (Ser473) pAb (Cell Signaling) for WB; anti-total Akt pAb (Cell Signaling) for WB; anti-phospho-p44/42 MAP kinase (T202/Y204) mAb (Cell Signaling) for WB; anti-active GSK3 a/b (Ser21/9) pAb (Cell Signaling) for WB, anti-GAP-DH mAb (Research Diagnostics Inc.) for WB, anti-c-Jun pAb (Santa Cruz) for WB. In all IPs, protein lysates were incubated in HNTG buffer (20 mm HEPES, pH 7.5, 150 mm NaCl, 0.1% Triton X-100, 10% glycerol, and 0.2 mm Na 3 VO 4 ) at 41C for 4 h with the primary antibodies, and then agarose beads conjugated with Protein A (Calbiochem) (for IP of pAbs) or anti-mouse IgG (Sigma) (for IP of mouse mAbs) were added for another 1 h. In control samples, the primary Abs were omitted. The immunoprecipitated proteins were washed three times with the HNTG buffer, separated by SDS-PAGE (polyacrilamide gel elecrophoresis), and analysed by WB and ECL chemiluminescence (Amersham). The intensity of bands representing relevant proteins was measured by the Scion Image laser densitometry scanning program.
Pulse-chase labeling
To determine the half-life of IRS molecules, we followed the methodology described by Lee et al. (2000) and Zhang et al. (2000) with some modifications. Briefly, 70% cultures were shifted to methionine-and cysteine-free DMEM (Gibco) for 16 h and then metabolically labeled with 35 S (100 mCi/1 ml, Express protein labeling mix, Perkin-Elmer) for 1 h. After that, the labeling medium was replaced with SFM. The cells were lysed at 2, 4, 8, and 12 h to obtain cytoplasmic proteins. The protein lysates were precipitated with anti-IRS-1 and IRS-2 Abs for 4 h and IPs were separated by SDS-PAGE as described above. Labeled IRS molecules were identified by autoradiography.
Confocal microscopy
Confluent cultures (50%) were fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100, washed 3 Â with PBS, and incubated for 1 h with primary antibodies (anti-IRS-1 CT (UBI) 2 mg/ml and anti-ER-a F-10 (Santa Cruz) 2 mg/ml), then washed with PBS 3 Â , and incubated with secondary Abs. A fluoresceine-conjugated donkey anti-mouse IgG (Calbiochem) was used as a secondary Ab for ER-a and a rhodamineconjugated donkey anti-rabbit IgG (Calbiochem) was used for IRS-1. The cellular localization of IRS-1 and ER-a was studied with Bio-Rad MRC 1024 confocal microscope connected to a Zeiss Axiovert 135 M inverted microscope. The optical sections were taken at the central plane. The fluorophores were imaged separately to ensure no excitation/emission wavelength overlap.
